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Introduction:
Celecoxib I, a sulfonamide acting as dual cyclooxygenase -carbonic anhydrase (CA, EC 4.2.1.1) inhibitor, 1 was considered to be an attractive target for designing CA inhibitors (CAIs) which may possess a dual action on these two families of enzymes involved in various pathologies which cross-freact in some cases (e.g., glaucoma, cancer, arthritis). [2] [3] [4] [5] [6] . Celecoxib shows a nanomolar affinity for the cytosolic human (h) isoform hCA II (Ki= 21 nM), inhibiting even better the tumour associated enzymes hCA XI (Ki=16 nM) and hCA XII (Ki=18 nM). 1 These enzymes were recently validated as antitumor/antoimetastatic targets with one compounds (SLC-0111) in Phase Ib/II clinical trials. 2, 3 The X-ray crystal structure of celecoxib bound CA II (PDB code: 6cox) reported by one of our groups, 1 afforded the deep understanding of the groups important for interaction with the CA II active site. The sulfonamide group of I was observed to be coordinated to Zn +2 in a tetrahedral coordination geometry, whereas the trifluormethyl group occupied the hydrophobic pocket, located in one half of the active site. 1a Unexpectedly, the p-toyl moiety of the drug was observed to point towards the hydrophilic half of the active site, making favourable contacts with residues Asn67, Glu69 and Gln92. An analysis of a modelling study, of celecoxib and CA IX protein, showed a similar mode of interaction between the sulfonamide and the active site, as in the hCA II -celecoxib complex analysed by X-ray crystallography ( Figure 2A ). Our current model of designing selective CAIs is based on designing a scaffold that can be substituted with less polar groups (Ar 1 and Ar 2 in Figure 2B ), in order to fill in the unoccupied hydrophobic pocket ( Figure 2B ). In view of the aforementioned facts and in continuation of our earlier work on the design of inhibitors of these enzymes, 1-3 it was envisaged to incorporate the bulky pyridotriazolopyrimidine (PTP) scaffold as tail to the benzene-sulfonamide motif. We aimed to exploit the unoccupied hydrophobic region shown in Figure 2A , within the active site of CA IX, hypothesizing that the aryls at position 6 and 8 of the PTP scaffold may interact in a favorable manner with the enzyme active site, as shown schematically in Figure 2C . We report herein the synthesis and the carbonic anhydrases inhibition evaluation of the new such derivatives, incorporating the bulky PTP scaffold.
Results and discussion:

Chemistry:
Our proposed synthetic methodology to the desired pyridotriazolopyrimidine scaffold containing sulfonamide moiety is depicted in Scheme 1, Scheme 2 and Scheme 3. The synthesis of the 6-amino-2-thiouracil (3) was accomplished as reported by refluxing ethyl cyanoacetate
(1) with thiourea (2) in sodium ethoxide. 8 The condensation of the 6-amino-2-thiouracil (3) with different aromatic α-β unsaturated ketones, β-enaminones, diketones and aldehydes was reported as convenient and efficient strategy to synthesize substituted pyrido [2,3-d] pyrimidines. [9] [10] [11] [12] [13] reported that the reaction of the 6-amino-2-thiouracil (3) The synthesis of the key pyrido[2,3-d]pyrimidines 5a-j was accomplished via reacting 6-amino-2-thiouracil 3 and different α-β unsaturated aromatic ketones 4a-j 14 in refluxing dry DMF under air in 40-65% yields (Scheme 1). The structures assigned to compounds 5a-j were confirmed by 1 H and 13 C NMR. 1 H NMR spectra of the synthesized pyrido [2,3-d]pyrimidines showed the presence of a singlet at δ 7.56-8.07 ppm integrated to the pyridine ring proton and two NH singlet signals at δ 12. 23-12.41 and 12.90-13. 10 ppm corresponding to two NHs of the pyrimidine ring. Furthermore, 13 C NMR spectra of 5a-c revealed the signals of the pyridine H at δ 108. 20-108.27 ppm and the signal of thioxo carbon at δ 175. 41-175.43 ppm.
The hydrazonoyl chlorides 11a and 11b synthesis were started with the chlorination of the active methylene group of acetylacetone 7a and ethyl acetoacetate 7b using sulphuryl chloride to afford the α-chloroacetyl derivatives 8a and 8b, as described by Alihn in 1878. 15 Then by applying Japp-Klingemann coupling of the aforementioned α-chloroacetyl derivatives (8a and 8b) with the diazonium salts of sulfanilamide 10, we have got the acetyl derivative 11a and the ester derivative 11b in reasonable yields (65 and 72%, respectively) (Scheme 2 [16] [17] [18] [19] This reaction proceeds via 1,3-dipolar cycloaddition of hydrazonoyl chlorides with dipolarophile thiones. 17 A literature review of this reaction almost exclusively prefers isomer 16 over 15 (Scheme 3). This suggest that the reaction process through the cyclo-addition of carbon 2 and nitrogen 3 of the pyrido[2,3-d]pyrimidine thiones with the hydrazonoyl chloride derivative in presence of base (Scheme 3). 17 The reaction mechanism was postulated to start with S-alkylation of the thiouracil derivative to afford the thiohydrazontes 12. In the presence of base, the nucleophilicity of the terminal hydrazone N increases and the compound undergoes Chapmanlike rearrangement to give the corresponding thiohydrazide 13. 
Carbonic anhydrase inhibition:
All the synthesized derivatives 16a-16t were evaluated for their efficacy in inhibiting four relevant CA isoforms, i.e., hCA I, II, IV and IX, by using the stopped flow carbon dioxide hydrase assay 22 , in comparison to acetazolamide (AAZ) as a standard CAI.
In general, all the assayed compounds displayed good inhibitory action against the reported hCA isoforms, with K I spanning from the low micromolar to the low-medium nanomolar range.
In detail, the following structure−activity-relationship (SAR) can be gathered from the data reported in Table 1 , for each tested isoform: (iv) Finally, the tumor-associated isoform hCA IX was potently inhibited by the most of the reported sulfonamides with K I reaching the low-medium nanomolar range (0.16 -3.26 μM).
In particular, the acetyl bearing derivatives 16a, 16c, 16e, 16g and 16i from series I and 16m
and 16s from series II, displayed a nanomolar inhibitory profile (K Is of 0. 18, 0.25, 0.35, 0.33, 0.33, 0.19 and 0.16 μM, respectively) (v) Despite the not enviable efficacy that sulfonamides 16a-16t showed against the tumorassociated isoform (celecoxib and AAZ displayed K I s of 0.02 and 0.03 μM), it is reasonable to focus the attention on the interesting selective profile they possess against hCA IX versus hCA II (Table 2) . Indeed, it is satisfying to note that most of the reported compounds displayed a selectivity ratio hCA IX/hCA II from two-fold to fourteen-fold higher than celecoxib or AAZ.
Only 16k, 16l and 16n were non-selective hCA IX over hCA II inhibitors. On the other hand, all the acetyl PTP sulfonamides from the series I and 16k and 16m from series II were shown to possess much better selectivity for the tumor-associated isoform hCA IX over hCA IV, compared to the corresponding carboxyethyl analogues and AAZ, while exhibited comparable selectivity ratio with celecoxib. A different behaviour may be highlighted for the remaining derivatives of series II. In fact, the carboxyethyl bearing sulfonamides 16p, 16r and 16t were more selective inhibitors of hCA IX over hCA IV in comparison to their acetyl analogues. In addition, 16p and 16r displayed selectivity ratio hCA IX/IV comparable to celecoxib, being four-fold better than AAZ.
(vi) As more than once highlithed here, the data reported in Table 1 clearly demonstrate that the replacement of the acetyl group in position R 1 by the carboxyethyl moiety generally worsened the inhibition profiles of derivatives 16a-16t depending on the substituents Ar 1 , R 2 and the considered isoform.It is reasonable to hypothesize that such a diminished inhibitory efficacy of the carboxyethyl derivatives in comparison to the acetyl ones might derive from the steric hyndrance aroused by the PTP. Indeed, such a bulky core may lead to a rather rigid and fixed positioning of the tricyclic scaffold within the active site pocket, obviously depending on the substituents Ar 1 and R 2 . Hence, in most cases the replacement of the acetyl group with the bigger carboxyethyl moiety may cause clashes with amino acid residues from the hydrophobic pocket, worsening thus the inhibitory activity. 
Conclusions
Two novel series of sulfonamides, 16a-16j and 16k-16t, containing the pyridotriazolopyrimidine scaffold have been synthesized and evaluated in vitro as inhibitors against four relevant hCAs, comprising the cytosolic and ubiquitous isozymes hCA I and II as well as the transmembrane hCA IV and hCA IX, the last one a validated antitumor drug target.
Most of the reported sulfonamides acted as good, low micromolar inhibitors of hCA I, II and IV, whereas they displayed a better efficacy in inhibiting the tumor-associated isoform hCA IX. Many derivatives herein reported highlighted better selectivity ratios for inhibiting hCA IX over hCA II than celecoxib and AAZ. Conversely, some sulfonamides among the two series demostrated a comparable selectivity for hCA IX over hCA IV, similar to celecoxib, whereas being 3 to 6-fold better than AAZ. Considering that isoform hCA IX is a validated target for the diagnosis and treatment of cancers, discovery of selective inhibitors represents a promising step to unveil a more effective cancer therapy, and moreover the obtained SAR might further help in the design of novel, isoform-selective inhibitors. Melting points were measured with a Stuart apparatus and were uncorrected. The NMR spectra were recorded by Varian Gemini-300BB 300, 400 and 500 MHz FT-NMR spectrometers (Varian Inc., Palo Alto, CA). 1 H spectra were run at 300, 400 and 500 MHz and 13 C spectra were run at 75, 100 and 125 MHz, respectively, in deuterated dimethylsulphoxide (DMSO-d 6 ).
Chemical shifts (δ H ) are reported relative to TMS as internal standard. All coupling constant (J) values are given in hertz. The abbreviations used are as follows: s, singlet; d, doublet; t, triplet, m, multiplet. Microanalyses were carried out using Perkin Elmer PE 2400 CHN Elemental Analyzer and the results were within ±0.4%. Analytical thin layer chromatography (TLC) on silica gel plates containing UV indicator was employed routinely to follow the course of reactions and to check the purity of products. All reagents and solvents were purified and dried by standard techniques. 6-Amino-2-thiouracil (3), 23 hydrazonoyl chlorides 11a, 11b, 18 pyrido[2,3-d]pyrimidines 5d, 5e, 5g were prepared according to the literature procedure. 12 
General procedure for preparation of 5-aryl-7-(thiophen-2-yl / 4-chlorophenyl)-2-thioxo-2,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one (5a-j) and spectral data is depicited in
the supplementary file.
General procedure for preparation of target compounds (16a-t).
To a mixture of 5-aryl-
(5a-j) (1 mmol) and the appropriate hydrazonoyl chloride 11a, b (1 mmol) in dioxane (30 mL), triethylamine (0.14 mL, 1 mmol) was added. The reaction mixture was refluxed until the starting materials were fully consumed or until conversion was observed to stall (monitored by TLC). The solvent was removed under vacuum and the residue was triturated with methanol.
The formed solid was washed thoroughly with water, filtered then crystallized from DMF:EtOH [v:v, 1:1] or subjected to flash chromatography (methanol/dichloromethane, 1:10)
to give 16a-t. Compounds 16k and 16l were previously synthesized in our laboratory. 2, 4] triazolo [4,3-a] 11, 108.04, 119.31, 120.69, 127.71, 128.19, 128.61, 128.93, 129.43, 130.14, 136.20, 136.44, 139.26, 139.58, 142.23, 142.70, 147.67, 155.12, 155.52, 160.27, 160.31, 188.03; Anal. Calcd for C 28 H 19 ClN 6 O 4 S: C, 58.90; H, 3.35; N, 14.72. Found: C, 59.20; H, 3.56; N, 2, 4] triazolo [4,3-a] 13.72, 63.63, 107.39, 118.77, 120.26, 127.21, 127.72, 128.18, 128.47, 128.94, 129.65, 135.73, 135.87, 135.98, 138.76, 139.03, 142.24, 146.63, 154.57, 154.76, 156.12, 159.79, 159.90; Anal. Calcd for C 29 H 21 ClN 6 O 5 S: C, 57.95; H, 3.52; N, 13.98. Found: C, 57.76; H, 3.87; N, 2, 4] triazolo [4,3-a] 118.88, 120.20, 127.21, 128.93, 129.64, 135.26, 135.29, 135.76, 135.88, 138.74, 141.73, 142.24, 146.81, 159.79, 161.24, 163.19, 187.51; Anal. Calcd for C 28 H 18 ClFN 6 O 4 S: C, 57.10; H, 3.08; N, 14.27. Found: C, 57.46; H, 3.36; N, 2, 4] triazolo [4,3-a] 13.74, 63.65, 107.46, 118.86, 120.28, 127.22, 128.97, 129.68, 130.69, 135.28, 135.77, 135.87, 135.96, 138.74, 142.27, 146.62, 153.46, 154.85 ( 1 J F-C = 159. 18 Hz), 159.86, 159.90, 161.27, 163.21; Anal. Calcd for C 29 H 20 ClFN 6 O 5 S: C, 56.27; H, 3.26; N, 13.58. Found: C, 56.56; H, 3.59; N, [1, 2, 4] triazolo [4,3-a] 18, 118.00, 120.96, 127.91, 128.42, 129.67, 130.37, 131.05, 133.76, 136.49, 136.59, 138.57, 139.43, 142.42, 142.95, 147.57, 153.93, 155.80, 160.48, 160.64, 188.26 4.4.3.6. Ethyl 6, [1, 2, 4] triazolo [4,3-a] 14.43, 64.35, 108.00, 119.40, 120.98, 127.91, 128.42, 129.66, 130.36, 131.07, 133.78, 136.51, 136.54, 136.59, 138.53, 139.40, 142.98, 147.32, 153.85, 155.51, 156.78, 160.55, 160.64; Calcd for C 29 H 20 Cl 2 N 6 O 5 S: C, 54.81; H, 3.17; N, 13.23. Found: C, 55.09; H, 3.30; N, [1, 2, 4] triazolo [4,3-a] H, 3.52; N, 13.98. Found: C, 58.00; H, 3.76; N, [1, 2, 4] triazolo [4,3-a] 10; H, 3.67; N, 13.32; Found: C, 57.32; H, 3.86; N, [1, 2, 4] triazolo [4,3-a] 107.70, 118.89, 120.79, 123.29, 127.71, 129.46, 130.15, 130.34, 136.17, 136.44, 139.14, 142.13, 142.84, 146.42, 147.40, 147.68, 152.61, 155.51, 160.08, 160.63, 187. , 15.92; Found: C, 54.86; H, 3.18; N, [1, 2, 4] triazolo [4,3-a] , 3.12; N, 15.18. Found: C, 54.27; H, 3.36; N, pyrido [2,3-d] [1, 2, 4] triazolo [4,3-a] 
